WillItSurvive
Robotics and industrial automation · United Kingdom

CMR Surgical

cmrsurgical.com ↗

UK maker of the Versius surgical robot, chasing Intuitive and Medtronic into US hospitals.

Losing its protection
Assessed 24 July 2026 · Evidence as of 24 July 2026
The structural protection is eroding.
On the recordSince 24 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: FDA decision on Versius Plus gynecology 510(k), filed April 2026
The call

CMR has a cleared product and paying hospitals, but it is entering the US at the same moment Medtronic ships a rival system into its exact market.

CMR Surgical builds robotic arms that help surgeons perform soft-tissue operations like gynecology and colorectal procedures. The company got government approval and has deals with 160-plus hospitals, but that does not stop much larger competitors from building the same thing. Intuitive Surgical already controls the market with its da Vinci system in thousands of hospitals, and Medtronic just got approval for its Hugo robot in the exact same medical area CMR is targeting, so CMR is now fighting two well-funded giants. The real question is whether CMR can place enough robots in enough hospitals and do enough surgeries in the next year or two before running out of cash, especially since the company has spent billions to generate less than $70 million in revenue.

Why
01
AI pressure: None apparent. No AI system currently reads or performs soft tissue surgery, so the pressure on CMR is hardware and regulatory, not model based. Could AI do the core job? Only partly.
02
Bigger players: Medtronic Hugo RAS. Hugo cleared FDA in Dec 2025 for the same soft tissue procedures CMR just entered, backed by Medtronic's sales force and balance sheet. Could a giant copy it? Yes, easily.
03
What protects it. FDA clearances, 160+ hospital partnerships, and a 45,000 procedure dataset give CMR a working system and real customers, not just a plan.
What would change this call
FDA ruling on CMR's gynecology 510(k), submitted Apr 2026. Approval would expand CMR's addressable procedures; denial would stall US growth.
Number of US hospital placements CMR reports vs Medtronic Hugo RAS in 2026. Shows whether CMR can gain share or is being outpaced in its first US year.
Terms of CMR's next funding round, likely 2026-27. A down-round or heavy debt component would confirm capital strain versus its $3B 2021 valuation.
Key numbers
  • 45,000+ patients treated globally (2026-03)
  • $3B valuation, unchanged since 2021 round (2021-06)
  • 160+ hospital partnerships worldwide (n.d.)
Named risks
  • Headcount fell 44.6 percent from 2023 to 2025, signaling cost pressure or contraction. Severity: high
  • Three way US soft tissue robotics contest with Intuitive and newly cleared Medtronic Hugo in CMR's first US year, 2026. Severity: high
  • April 2025 funding round included $68M in debt while valuation stayed flat at $3B since 2021. Severity: medium
  • Independent revenue estimates for 2023 to 2024 are far below the roughly $1.35B raised, suggesting slow path to self-sufficiency. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Intuitive Surgicallosing toda Vinci has 10,000+ installed systems and ~$180B market cap vs CMR's 45,000 total patients treated by Mar 2026
Medtronic (Hugo RAS)gaining onHugo RAS FDA cleared Dec 2025, entering CMR's exact soft tissue segment just as CMR debuted in the US, Mar 2026
Distalmotion (Dexter)contestingVC backed Swiss rival offering two arm laparoscopy compatible with existing hospital infrastructure
Questions people ask
Is CMR Surgical profitable in 2026?
No profitability has been disclosed. CMR Surgical has raised roughly $1.35 billion in total funding as of July 2026 while independent revenue estimates for 2023 to 2024 sit far lower, in the tens of millions, suggesting the company remains capital intensive and pre profitability.
Who owns CMR Surgical?
CMR Surgical is privately held and venture backed, with shareholders including SoftBank Vision Fund 2, Tencent, Ally Bridge Group, RPMI Railpen, LGT and Trinity Capital (as a debt provider). It reached a roughly $3 billion valuation after a $600 million Series D in June 2021, unchanged since.
Who is CMR Surgical's biggest competitor?
Intuitive Surgical (da Vinci), with roughly $180 billion market cap and over 10,000 installed systems, dominates the market CMR entered in the US in March 2026. Medtronic's Hugo RAS, FDA cleared in December 2025, directly targets CMR's same soft tissue surgery segment.
Could AI replace CMR Surgical's Versius system?
Unlikely to replace it outright. As of July 2026, CMR is integrating NVIDIA's Isaac for Healthcare simulation platform (Cosmos H Dreams) into Versius Plus to add predictive guidance, per a July 22, 2026 announcement, but this is shared industry technology layered onto CMR's hardware and clearances, not a substitute for them.
Has CMR Surgical gotten FDA approval to sell Versius in the US?
Yes. Versius received FDA De Novo marketing authorization in October 2024, and the next generation Versius Plus received 510(k) clearance for cholecystectomy in December 2025, followed by a US commercial debut announced at SAGES in March 2026.
Is CMR Surgical's valuation still $3 billion in 2026?
The $3 billion figure dates to a June 2021 Series D round and was still referenced in an April 2025 financing of over $200 million that combined equity with $68 million in debt from Trinity Capital, indicating no confirmed valuation increase in nearly five years.
Timeline
  • 2026-07-22CMR Surgical and NVIDIA showcase Cosmos H Dreams AI simulation for Versius Plus at SRS 2026
  • 2026-04-29CMR submits 510(k) to FDA to expand Versius Plus into benign gynecology
  • 2026-03-26CMR announces US commercial debut at SAGES 2026 and 45,000 patients treated globally
  • 2025-12Versius Plus receives FDA 510(k) clearance for cholecystectomy; Medtronic Hugo RAS also FDA cleared
  • 2025-04-04CMR raises over $200M in equity and debt, including $68M debt from Trinity Capital
  • 2025-01-14Massimiliano Colella formally appointed CEO after serving as interim since Oct 2024
  • 2024-10Versius receives FDA De Novo marketing authorization in the US
  • 2023-09CMR raises roughly $164 to 165 million led by Watrium AS
  • 2023-04CMR announces about 350 redundancies
  • 2021-06-27CMR raises $600M Series D at roughly $3 billion valuation, led by SoftBank
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Bright MachinesNidec CorporationMobile Industrial Robots (MiR)
More in Robotics and industrial automation →
Sources